肿瘤免疫治疗是指利用人体的免疫机制,通过主动或被动的方法增强患者免疫功能,达到杀伤肿瘤细胞的目的。嵌合抗原受体T细胞（CAR-T）作为肿瘤免疫治疗的新型精准靶向疗法,近几年通过优化和改良已成功应用于多种血液肿瘤的治疗,是目前恶性肿瘤治疗中最有潜力的疗法之一。但由于实体瘤中存在显著的异质性和复杂的肿瘤免疫微环境,CAR-T在实体瘤中的应用仍面临诸多挑战。本文将对目前 CAR-T 细胞治疗实体瘤的研究成果、现存挑战及相应的优化策略进行综述,以期为后续 CAR-T 细胞治疗实体肿瘤研究提供参考。

Tumor immunotherapy is the process of enhancing patients’ immune system through active or passive methods to achieve the goal of eliminating tumor cells．Through optimization and modification,chimeric antigen receptor T cells（CAR-T）,a novel precise targeted therapy of cancer immunotherapy,have been successfully used in the treatment of several hematological malignancies in recent years．CAR-T is considered as one of the most promising therapies for the treatment of malignant tumors at the moment．However,application of CAR-T in solid tumors still confronts several difficulties due to the high heterogeneity and intricate tumor immune microenvironment．To serve as a reference for future CAR-T cell therapy for solid tumors,the present research findings,current difficulties and associated optimization techniques are reviewed in this paper．

大便失禁是肛肠外科常见疾病,可导致患者生活质量下降,并引起一系列社会心理问题,其发病率随着年龄增加明显上升。肛门括约肌复合体损伤是大便失禁的最常见原因。目前的治疗方式包括保守治疗和手术治疗,但治疗效果仍不理想,尤其是长期治疗效果较差。最近,许多临床前和临床研究对大便失禁的干细胞疗法进行了探索,作为一种新的治疗方式,干细胞疗法有望彻底治愈大便失禁。本文就干细胞疗法治疗大便失禁的动物模型、损伤和修复机制、疗效等方面进行综述。

Fecal incontinence is a common anorectal surgical condition that can lead to decreased quality of life and a range of psychosocial problems in patients, and its incidence increases significantly with age. Damage to the anal sphincter complex is the most common cause of fecal incontinence. Current treatment modalities include conservative and surgical treatment, but treatment outcomes remain suboptimal, especially in the long term. Recently, many preclinical and clinical studies have explored stem cell therapy for fecal incontinence as a new treatment modality that holds promise for a complete cure of fecal incontinence. This paper presents a review of animal models, mechanisms of injury and repair, and efficacy of stem cell therapy for fecal incontinence.